miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1503-1510

  Jin, Ke ^a   Xiang, Yonghua ^a   Tang, Jing ^a   Wu, Guangchun ^a   Li, Junwei ^a   Xiao, Huaichun ^a   Li, Chunwang ^a   Chen, Yuxiang ^b   Zhao, Jingfeng ^b  

^a HUNAN CHILDREN'S HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Gallbladder cancer; miR 34a; Prognosis; Telomere length

Indexed keywords

ADENOVIRUS VECTOR; MICRORNA 34A; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURGERY; CELL ISOLATION; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GALLBLADDER ADENOCARCINOMA; GALLBLADDER CARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; CELL LINE, TUMOR; FEMALE; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICRORNAS; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROGNOSIS; TELOMERE HOMEOSTASIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898844587     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1207-z     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71-96.
2. Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331-42.
3. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310-5. (Pubitemid 40486772)
4. Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647-52.
5. Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24:1069-78.
6. Park SB, Kim YH, Rho HL, Chae GB, Hong SK. Primary carcinosarcoma of the gallbladder. J Korean Surg Soc. 2012;82:54-8.
7. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515-24. (Pubitemid 43345317)
8. Bagga S, Pasquinelli AE. Identification and analysis of microRNAs. Genet Eng (N Y). 2006;27:1-20.
9. Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010;29:4980-8.
10. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731-43. (Pubitemid 46856247)
11. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586-93. (Pubitemid 47327945)
12. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433-8. (Pubitemid 47437414)
13. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298-307. (Pubitemid 47176893)
14. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745-52. (Pubitemid 46856245)
15. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591-600.
16. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107-10.
17. Sahin E, DePinho RA. Axis of ageing: telomeres, p53 and mitochondria. Nat Rev Mol Cell Biol. 2012;13:397-404.
18. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30:e47.
19. Hu Y, Ou Y, Wu K, Chen Y, Sun W. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biol. 2012;33:1863-70.
20. Zhang X, Kon T, Wang H, Li F, Huang Q, Rabbani ZN, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 2004;64:8139-42. (Pubitemid 39491746)
21. Ogawa T, Saiki Y, Shiga K, Chen N, Fukushige S, Sunamura M, et al. miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. Cancer Sci. 2012;103:1737-43.
22. Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903-9.
23. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193-9.
24. Eisenberg DTA. An evolutionaty review of human telomere biology: The thirty telomere hypothesis and notes on potential adaptive paternal effects. Am J Hum Biol. 2011;23:149-67.
25. Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta. 2009;1792:317-23.
26. Bisofti M, Heaphy CM, Griffith JK. Telomeres: Prognostic markers for solid tumors. Int J Cancer. 2006;119:2255-60. (Pubitemid 44546943)
27. Avigad S, Naumov I, Ohali A, Jeison M, Berco GH, Mardoukh J, et al. Short telomeres: a novel potential predictor of relapse in Ewing sarcoma. Clin Cancer Res. 2007;13:5777-83. (Pubitemid 47591641)
28. Shirotani Y, Hiyama K, Ishioka S, Inyaku K, Awaya Y, Yonehara S, et al. Alteration in length of telomeric repeats in lung cancer. Lung Cancer. 1994;11:29-41. (Pubitemid 24244393)
29. Hirashima T, Komiya T, Nitta T, Takada Y, Kobayashi M, Masuda N, et al. Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer. Anticancer Res. 2000;20:2181-7. (Pubitemid 30636205)
30. Frías C, García-Aranda C, De Juan C, Morán A, Ortega P, Gómez A, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates withDNArepair impairment in nonsmall cell lung cancer. Lung Cancer. 2008;60:416-25.
31. Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, et al. CD44+CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010;11:1182-90.
32. Kim H, Lee OH, Xin H, Chen LY, Qin J, Chae HK, et al. TRF2 functions as a protein hub and regulates telomere maintenance by recognizing specific peptide motifs. Nat Struct Mol Biol. 2009;16:372-9.